UA106361C2 - Фармацевтическая композиция для лечения эссенциальной тромбоцитемии - Google Patents

Фармацевтическая композиция для лечения эссенциальной тромбоцитемии

Info

Publication number
UA106361C2
UA106361C2 UAA201108389A UAA201108389A UA106361C2 UA 106361 C2 UA106361 C2 UA 106361C2 UA A201108389 A UAA201108389 A UA A201108389A UA A201108389 A UAA201108389 A UA A201108389A UA 106361 C2 UA106361 C2 UA 106361C2
Authority
UA
Ukraine
Prior art keywords
anagrelide
pharmaceutical composition
treatment
essential thrombocythemia
particles
Prior art date
Application number
UAA201108389A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рудольф Видманн
Original Assignee
Аоп Орфан Фармацейтикалс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аоп Орфан Фармацейтикалс Аг filed Critical Аоп Орфан Фармацейтикалс Аг
Publication of UA106361C2 publication Critical patent/UA106361C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к фармацевтической композиции в форме таблетки или капсулы, включающей частицы анагрелида и по меньшей мере 60 мг моногидрата лактозы, при этом по меньшей мере 90 % указанных частиц анагрелида имеют диаметр меньше 10 мкм, которая в комбинации с моногидратом лактозы позволяет получить лекарственную форму со сниженными характеристиками высвобождения при приеме пациентом. Также указанная композиция может дополнительно содержать повидон, кросповидон, микрокристаллическую целлюлозу и/или стеарат магния. Кроме того, изобретение относится к применению указанной выше фармацевтической композиции и способу лечения эссенциальной тромбоцитемии указанной выше фармацевтической композицией.
UAA201108389A 2008-12-05 2009-12-04 Фармацевтическая композиция для лечения эссенциальной тромбоцитемии UA106361C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0070708U AT10562U3 (de) 2008-12-05 2008-12-05 Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
PCT/EP2009/066405 WO2010063824A1 (en) 2008-12-05 2009-12-04 Novel composition for treatment of essential thrombocythemia

Publications (1)

Publication Number Publication Date
UA106361C2 true UA106361C2 (ru) 2014-08-26

Family

ID=40550008

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201108389A UA106361C2 (ru) 2008-12-05 2009-12-04 Фармацевтическая композиция для лечения эссенциальной тромбоцитемии

Country Status (20)

Country Link
EP (1) EP2367539B1 (ru)
KR (1) KR101631728B1 (ru)
CN (1) CN102307572B (ru)
AT (1) AT10562U3 (ru)
AU (1) AU2009324043B2 (ru)
CY (1) CY1114306T1 (ru)
DK (1) DK2367539T3 (ru)
EA (1) EA022715B1 (ru)
ES (1) ES2426232T3 (ru)
HK (1) HK1158957A1 (ru)
HR (1) HRP20130647T1 (ru)
IL (1) IL213198A (ru)
MY (1) MY155660A (ru)
PL (1) PL2367539T3 (ru)
PT (1) PT2367539E (ru)
SG (1) SG171979A1 (ru)
SI (1) SI2367539T1 (ru)
UA (1) UA106361C2 (ru)
WO (1) WO2010063824A1 (ru)
ZA (1) ZA201103409B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011231557B2 (en) * 2010-03-25 2016-05-26 Aop Orphan Pharmaceuticals Ag Novel composition for treatment of essential thrombocythemia
HUE055943T2 (hu) * 2014-03-07 2022-01-28 Galenicum Health S L U Anagrelidet tartalmazó gyógyszerkészítmények
AU2015370666B2 (en) * 2014-12-22 2020-09-03 Arovella Therapeutics Limited Prevention and treatment of metastatic disease in thrombocytotic cancer patients
WO2022060309A1 (en) * 2020-09-18 2022-03-24 İlko İlaç Sanayi̇ Ve Ti̇caret A.Ş. Long-term stable anagrelid capsule composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US20050008704A1 (en) * 2003-07-11 2005-01-13 Ray Anup Kumar Pharmaceutical composition for solubility enhancement of hydrophobic drugs
MXPA06012701A (es) * 2004-05-05 2007-02-14 Celgene Corp Metodo de utilizacion y composiciones que comprenden farmacos inhibidores de citocina selectivos para el tratamiento y manejo de enfermedades mieloproliferativas.
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
CN101198314A (zh) * 2005-04-12 2008-06-11 伊兰制药国际有限公司 纳米微粒喹唑啉衍生物制剂
US20070104782A1 (en) * 2005-07-28 2007-05-10 Ibrahim Melissa E Modified release tablet formulations with enhanced mechanical properties
WO2007016350A2 (en) * 2005-07-28 2007-02-08 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
CN101588794A (zh) * 2007-01-25 2009-11-25 万能药生物有限公司 调节释放药物组合物及其制备方法

Also Published As

Publication number Publication date
CY1114306T1 (el) 2016-08-31
AU2009324043A1 (en) 2010-06-10
HRP20130647T1 (en) 2013-08-31
KR20110106280A (ko) 2011-09-28
EP2367539B1 (en) 2013-06-05
PT2367539E (pt) 2013-09-09
WO2010063824A1 (en) 2010-06-10
SI2367539T1 (sl) 2013-09-30
IL213198A (en) 2015-09-24
AT10562U3 (de) 2010-01-15
AT10562U2 (de) 2009-06-15
EA201170583A1 (ru) 2011-12-30
MY155660A (en) 2015-11-13
PL2367539T3 (pl) 2013-10-31
CN102307572A (zh) 2012-01-04
KR101631728B1 (ko) 2016-06-17
IL213198A0 (en) 2011-07-31
SG171979A1 (en) 2011-07-28
ES2426232T3 (es) 2013-10-22
EA022715B1 (ru) 2016-02-29
CN102307572B (zh) 2015-04-08
HK1158957A1 (en) 2012-07-27
EP2367539A1 (en) 2011-09-28
ZA201103409B (en) 2012-07-25
DK2367539T3 (da) 2013-08-26
AU2009324043B2 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
IL197574A0 (en) Pharmaceutical compositions
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
FI2498756T4 (fi) Neratinibimaleaatin tablettiformulaatiot
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2007048219A3 (en) Sustained drug release composition
UA103347C2 (ru) Фармацевтическая препаративная форма, которая содержит нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
NZ604055A (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MX2009007784A (es) Composiciones de tiacumicinas estables.
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
WO2007100614A3 (en) STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
UA106361C2 (ru) Фармацевтическая композиция для лечения эссенциальной тромбоцитемии
IL207928A (en) Pharmacotherapeutic agent that contains an active drug (mtx) and helps 2, 2-anhydropyrimidine to reduce and use mtx toxicity
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
MX2013001637A (es) Composiciones farmaceuticas de liberacion controlada oral de blonanserina.
EP2387392B1 (en) Pharmaceutical formulations of olmesartan
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
TW200716114A (en) Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
WO2011080570A3 (en) Extended release pharmaceutical composition comprising linezolid and process for preparing the same
UA100244C2 (ru) Фармацевтическая композиция гидрохлорида толперизона с контролируемым высвобождением